Rate , Predictors and Outcome of Chronic Migraine

NCT05079659 | Unknown DMC

• 1 other identifier: chronic migraine
• Study Type: observational
• Target: 296
• Locations: 1 country
• Sites: 1

Brief Summary

Nowadays, headache has been considered as one of the top global disabling medical conditions.1 Migraine is an important type of headache, and one of the chronic multifaceted neuro-inflammatory disorders.2 It is characterized by recurrent throbbing headache pain that typically affects one side of the head, and is often accompanied by nausea and disturbed vision. Migraine headache accounts for 1.4% of all neurological and mental disorders.2 It was reported that the estimated lifetime prevalence of migraine ranged 12%-18%.3 Chronic migraine is defined by the International Classification of Headache Disorders - ICHD-3 as having headaches for ≥ 15 days per month, for ≥ 3 months , which ≥ 8 days/month are linked to migraine. Chronic migraine affects around 1%-4% of the population and chronic tension-type headache about 2.2%.4 Approximately 25%-50% of those affected also have medication overuse headache, which has a population prevalence of 1%.5 Chronic headache is a severely disabling long-term condition, with higher symptom ,frequency and severity than episodic headache.6

Conditions

Chronic Migraine, Headache; Chronic Migraine

Outcome Measures

Primary Outcomes (1)

• To assess remission rate of chronic migraine to episodic migraine

  by assessing cases which remit from chronic migraine to episodic migraine according to the criteria of each of them

  2 years

Secondary Outcomes (1)

• to assess potential predictors of chronic migraine

  2 years

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

sample size was calculated using epidemiological information statistical package version 7. Based on paramaters for cross sectional study;proportion of remitted migraine .26 ,acceptable margin of error 0.05 ,design effect1.95% confidence level. The required sample size will be 296 migrainous patient .

You may qualify if:

• both sex 2- all age groups are included 3-history suggestive of chronic migraine 4-accept to participate in the study

You may not qualify if:

• presence of neurological disease other than chronic migraine 2-presence of other chronic medical conditions 3-patients refuse to participate in the study .

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut university

Asyut, Egypt

RECRUITING

Related Publications (8)

• Noor T, Sajjad A, Asma A. Frequency, character and predisposing factor of headache among students of medical college of Karachi. J Pak Med Assoc. 2016 Feb;66(2):159-64.

  PMID: 26819160 BACKGROUND

• van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits MG, de Roos NM. Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Front Neurol. 2014 Nov 21;5:241. doi: 10.3389/fneur.2014.00241. eCollection 2014.

  PMID: 25484876 BACKGROUND

• Semiz M, Senturk IA, Balaban H, Yagiz AK, Kavakci O. Prevalence of migraine and co-morbid psychiatric disorders among students of Cumhuriyet University. J Headache Pain. 2013 Apr 11;14(1):34. doi: 10.1186/1129-2377-14-34.

  PMID: 23578213 BACKGROUND

• Ibrahim N, Al-Kharboush D, El-Khatib L, Al-Habib A, Asali D. Prevalence and Predictors of Anxiety and Depression among Female Medical Students in King Abdulaziz University, Jeddah, Saudi Arabia. Iran J Public Health. 2013 Jul 1;42(7):726-36. eCollection 2013.

  PMID: 24427751 BACKGROUND

• Cousins G, Hijazze S, Van de Laar FA, Fahey T. Diagnostic accuracy of the ID Migraine: a systematic review and meta-analysis. Headache. 2011 Jul-Aug;51(7):1140-8. doi: 10.1111/j.1526-4610.2011.01916.x. Epub 2011 Jun 7.

  PMID: 21649653 BACKGROUND

• Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008 Sep;48(8):1157-68. doi: 10.1111/j.1526-4610.2008.01217.x.

  PMID: 18808500 BACKGROUND

• Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011 Feb 22;76(8):711-8. doi: 10.1212/WNL.0b013e31820d8af2. Epub 2011 Jan 26.

  PMID: 21270413 BACKGROUND

• McKenna SP, Doward LC, Davey KM. The Development and Psychometric Properties of the MSQOL: A Migraine-Specific Quality-of-Life Instrument. Clin Drug Investig. 1998;15(5):413-23. doi: 10.2165/00044011-199815050-00006.

  PMID: 18370497 BACKGROUND

MeSH Terms

Conditions

Headache

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

mostafa omar, master

CONTACT

01050659948; mostafa189199400@yahoo.com

tarek rageh, professor

CONTACT

01010077712; tarek-rageh@hotmail.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: DOCTOR

Study Record Dates

• First Submitted: September 28, 2021
• First Posted: October 15, 2021
• Study Start: January 1, 2021
• Primary Completion: April 1, 2023
• Study Completion: August 30, 2023
• Last Updated: October 15, 2021

Record last verified: 2021-10

Locations

EG (1)